Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

COVID-19 Vaccine and Potentially Related Thromboembolic Events: Case Series

Eman EL-Sawalhy*, Essa Kadiri, Eiman Elhouderi, Mohammed Abdelhalim, Marwa Sokrab, Jamila Asif, Maher Khadra, Khansae Nowir, Ayman Daoud, Faisal Musa

Department of Internal Medicine, Beaumont Hospital-Dearborn, MI

Abstract: The advent of multiple COVID vaccinations over the past year through an accelerated vaccine development process has led to concerns over its safety. The United States approved for emergency use the BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), ChAdOx1 nCoV-19 (Oxford-AstraZeneca), and the Ad26.COV2.S (Janssen/Johnson & Johnson) vaccines. Although these vaccines have had a high safety profile, rare but serious adverse events have been reported including pulmonary embolism (PE) and cerebrovascular thrombosis. In this case series, we identified three patients admitted to Beaumont Hospital with new onset of pulmonary thromboembolism shortly after receiving the Pfizer-BioNTech vaccine. Clinical and laboratory data were obtained and reviewed from the Epic charting system. The three patients included two male and one female patient. All were older than the age of 40, obese with a BMI > 30 kg/m², and had underlying vascular disorders including hypertension, coronary artery disease, and/or a history of a cerebrovascular accident. One patient was a current cigarette smoker, one had quit over 27 years ago, and the third patient never smoked. Two patients developed pulmonary embolism after the second dose of the Pfizer-BioNTech vaccine, while the third patient developed pulmonary embolism after the first dose. This case series illustrates a possible association between the Pfizer-BioNTech vaccine and the potential development of pulmonary thromboembolism, particularly in middle-aged, obese adults with underlying vascular disease. This is not surprising as recent research has seen higher incidence of thrombosis with other COVID-19 vaccinations including Moderna, Oxford-AstraZeneca, and Janssen/Johnson & Johnson. Identifying this possible association is crucial in early diagnosis and patient management, but more importantly in educating higher risk adults to avoid modifiable risk factors for venous thromboembolism including immobility, certain medications, and possibly postponing elective surgeries. Further prospective or retrospective cohort studies are warranted to assess this association.

Keywords: Pfizer-BioNTech vaccine, pulmonary embolism, deep venous thrombosis, safety

Received May 22, 2021; Revised June 28, 2021; Accepted July 08, 2021

Citation: Eman EL-Sawalhy, Essa Kadiri, Eiman Elhouderi, Mohammed Abdelhalim, Marwa Sokrab, Jamila Asif, Maher Khadra, Khansae Nowir, Ayman Daoud, Faisal Musa, COVID-19 Vaccine and Potentially Related Thromboembolic Events: Case Series. American Journal of Medical Case Reports, 9 (11). 527-531. January 2021. doi:10.12691/ajmcr-9-11-2

1. Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first reported in December of 2019 and rapidly evolved into a worldwide pandemic. Currently, COVID-19 has affected over 33 million individuals in the United States with a case-fatality ratio of 1.8 % [1]. It has a wide range of clinical manifestations from asymptomatic to critical illness. Symptoms can include fever, cough, malaise, myalgia, sore throat, diarrhea, nausea, anorexia, anosmia, ageusia, and shortness of breath [2]. COVID-19 can precipitate a severe inflammatory response resulting in acute respiratory distress syndrome (ARDs), prothrombotic states, multiorgan failure, and death.

Vaccinations remain a critical tool in reducing the number of cases and preventing the further spread of COVID-19. In December of 2020, the Food and Drug Administration (FDA) approved emergency use authorization (EUA) for two mRNA-type vaccines manufactured by Pfizer-BioNTech and Moderna [3]. In late February of 2021, a viral vector protein vaccine manufactured by Janssen/Johnson & Johnson, similar to the AstraZeneca vaccine authorized by the European Medicine Agency was also approved for EUA in the United States [3].

As of May 31, 2021, approximately 50% of the US population or 165 million individuals have received at least one vaccination dose [4]. Several cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), and both arterial and venous thrombosis with thrombocytopenia, were linked to both the Johnson & Johnson and Oxford-Astra Zeneca vaccines [5,6].

Here we present three cases of pulmonary embolism after receiving the Pfizer-BioNTech vaccine.

2. Case Presentation

2.1. Case 1

A 68-year-old female with well controlled hypertension and obesity with a BMI of 43.9 kg/m² presented to the hospital with complaints of sudden onset chest pain associated with dyspnea. She had received her second dose of Pfizer-BioNTech vaccine five days prior. She had no history of tobacco smoking, recent trauma, hospitalizations, or surgery, personal or family history of thrombophilia, underlying malignancy, prior confirmed COVID-19 infection, and was not any hormone replacement therapy.

Initial vitals were stable on room air and the physical exam was unremarkable. Blood work was significant for mildly elevated creatinine at 1.30 mg/dl, mildly elevated troponin (max 0.13 ng/ml), and elevated D-dimer of 4,071 ng/ml, otherwise electrolytes, cell blood count, PT/INR, and liver function tests were all within normal limits. An EKG showed normal sinus rhythm with no acute ischemic changes. Computed tomography angiography (CTA) of the chest was done which showed filling defects in the distal main pulmonary arteries, segmental upper and lower lobe branches bilaterally, and subsegmental right middle lobe and lingula branches compatible with acute pulmonary embolism (Figure 1). It also showed straightening of the intra-articular septum and right-left ventricular ratio greater than 1, compatible with right heart strain. Lower extremities venous doppler ultrasound showed no evidence of deep vein thrombosis (DVT).

She was diagnosed with acute pulmonary embolism and started on a heparin infusion. She subsequently received thrombolysis the following day and her symptoms improved. She was transitioned to apixaban (Eliquis) and discharged with instructions to follow up with hematology and oncology specialist for possible hypercoagulable workup and age-appropriate cancer screening. After few weeks, the patient had a hypercoagulable workup done including anticardiolipin antibody, beta 2 glycoprotein antibody, protein C, S, and activated protein C resistance that were negative.

Figure 1. CTA of the chest showing filling defects in the distal main pulmonary artery and segmental branches compatible with acute PE

2.2. Case 2

A 48-year-old male with coronary artery disease, heart failure with reduced ejection fraction resulting in ICD implantation, uncontrolled hypertension, hyperlipidemia, and current cigarette smoking (25-pack-year history) presented to the hospital with a 1-day history of intermittent aching substernal chest pain associated with exertional dyspnea and left upper extremity (LUE) paresthesia. He had received his first dose of Pfizer-BioNTech vaccine three weeks prior and noted progressive right upper extremity edema (RUE) and ecchymosis since being vaccinated. He had no recent trauma, hospitalizations, or surgery, personal or family history of thrombophilia, underlying malignancy, prior confirmed COVID-19 infection, and was not any hormone replacement therapy.

Figure 2. CTA of the chest showing small right lower lobe segmental pulmonary artery embolus (A). Venous doppler ultrasound of the right upper extremity showing an occlusive thrombosis of the right subclavian (B)

Initial vitals were stable on room air and physical exam was remarkable for proximal RUE edema with ecchymosis. Blood work was significant for up trending serial troponin 2.65->5.57->8.71 ng/ml and elevated D-dimer at 1,326 ng/ml, otherwise electrolytes, cell blood count, PT/INR, aPTT, and liver function tests were all within normal limits. An EKG showed normal sinus rhythm with no acute ischemic changes. Computed tomography angiography (CTA) of the chest showed a small right lower lobe segmental pulmonary artery embolus (Figure 2). Venous doppler ultrasound of the right upper extremity showed an occlusive thrombosis in the right subclavian, basilic, and cephalic veins (Figure 2). He was diagnosed with acute pulmonary embolism and non-ST segment elevation myocardial infarction (NSTEMI).

He was started on heparin infusion and taken for a cardiac catheterization the next day where he underwent percutaneous coronary intervention with drug eluting stent placement to the mid left anterior descending artery due to a 70% stenosis. His symptoms improved and he was transitioned to rivaroxaban (Xarelto). He was discharged with instructions to follow up with hematology and oncology specialist for possible hypercoagulable workup and age-appropriate cancer screening. After few weeks, the patient had a hypercoagulable workup done including anticardiolipin antibody, beta 2 glycoprotein antibody, protein C, S, and activated protein C resistance, prothrombin and Factor V mutation that were negative.

2.3. Case 3

An 80-year-old male with diabetes, congestive heart failure, and hyperlipidemia presented to the hospital with complaints of exertional dyspnea associated with chest pain and right leg edema. He had received his second dose of Pfizer-BioNTech vaccine four weeks prior. He has a 30 pack-year history of cigarette smoking, however, he quit at the age of 53. He had no recent trauma, hospitalizations, or surgery, personal or family history of thrombophilia, underlying malignancy, prior confirmed COVID-19 infection, and was not on any hormone replacement therapy.

Figure 3. CTA of the chest showing bilateral pulmonary embolism

Figure 4. Venous doppler ultrasound of the right lower extremity showed deep venous thrombosis of the right popliteal vein (A) and involving the right femoral vein (B)

Initial vitals were stable on room air and the physical exam was unremarkable. Blood work was significant for slightly elevated creatinine at 1.32 mg/dl, otherwise, electrolytes, cell blood count, PT/INR, aPTT, serial troponins, and liver function tests were all within normal limits. D-Dimer was not performed. An EKG showed normal sinus rhythm with no acute ischemic changes. Computed tomography angiography (CTA) of the chest showed bilateral pulmonary embolism with no signs of right heart strain (Figure 3). Venous doppler ultrasound of the right lower extremity showed deep venous thrombosis involving the right femoral vein and right popliteal vein (Figure 4). He was diagnosed with acute pulmonary embolism and right lower extremity deep vein thrombosis.

He was started on heparin infusion and his symptoms improved. He was transitioned to rivaroxaban (Xarelto) and discharged with instructions to follow up with hematology and oncology specialist for possible hypercoagulable workup and age-appropriate cancer screening.

3. Discussion

As of May 31, 2021, with a little over a year since the COVID-19 pandemic began, there have been an estimated 568,965 deaths from COVID-19 in the United States alone. According to the CDC, over 50% of the United States’ population have received at least one dose of the vaccine, while over 40% are fully vaccinated⁵. The CDC has found that 65-90% of individuals who are fully vaccinated with any of the three authorized vaccines are protected against symptomatic, laboratory-confirmed COVID-19 infection, while those who get infected, have reduced and less severe symptoms [4]. It is also noteworthy to point out that the vaccines have demonstrated a high efficacy (≥89%) in preventing COVID-19 infections, that are severe enough to require hospitalization. In addition, a growing body of evidence suggests that the vaccines also reduce asymptomatic infection and transmission [4].

This case series identified three patients who developed pulmonary embolism after receiving the Pfizer-BioNTech vaccine. Although all three of the patients were obese with a BMI > 30 kg/m² and had underlying cardiovascular disease, none had any obvious risk factors for venous thromboembolism, history of thrombophilia, or prior confirmed COIVD-19 infection. To our knowledge as of to date, there has been only one reported case of deep venous thrombosis associated with the Pfizer-BioNTech vaccine in a 66-year-old woman with no underlying medical conditions, a normal BMI, and no history of thrombophilia [7].

Since the introduction of COVID-19 vaccinations, there has been a growing number of cases of COVID-19 vaccine induced thrombosis associated with thrombocytopenia and in some cases bleeding, particularly with Janssen and AstraZeneca vaccines [8,9,10]. These reported cases occurred mostly in women under the age of 60, within 2-3 weeks of receiving the vaccine. Thromboses occurred in unusual sites, including cerebral venous sinus, splanchnic veins, and arteries accompanied by thrombocytopenia and bleeding [8,9,10]. The exact mechanism of thrombi formation is currently under investigation. Some hypothesize it to be related to an immunological response against platelet factor 4 leading to clotting formation and platelet consumption, similar to the mechanism of heparin-induced thrombocytopenia [8,9,10,11]. A recent study comparing the risk of cerebral thrombosis from COVID-19 infection and after vaccination with Pfizer-BioNTech or Moderna vaccines demonstrated an incidence of 39 per million in patient’s diagnosed with COVID-19 versus 4.1 per million in the vaccinated population [10]. The incidence of cerebral thrombosis in the general population is estimated between 2 to 5 per million, however recent evidence suggests that may be as high as 20 per million [12,13].

In our case series, the three patients had no laboratory evidence of thrombocytopenia, coagulation abnormalities, bleeding, or prior COVID infection. This leads us to consider an alternative mechanism by which the Pfizer-BioNTech vaccine might cause thromboses, different from the J Janssen/Johnson & Johnson and AstraZeneca vaccines.

4. Conclusion

This case series demonstrates a possible, albeit rare, likely association between the Pfizer-BioNTech vaccine and the development of venous thromboembolism. Further investigations are required to better elucidate this association and identify an underlying mechanism.

Conflict of Interest

None of the authors have any conflict of interest to declare.

Disclosure of Funding

None of the authors have any source of funding to declare.

References

[1]   | “Mortality Analyses.” Johns Hopkins Coronavirus Resource Center, coronavirus.jhu.edu/data/mortality.
[2]   | Gandhi, Rajesh T., et al. “Mild or Moderate Covid-19: NEJM.” New England Journal of Medicine, 21 Apr. 2021.
[3]   | Commissioner, Office of the. U.S. Food and Drug Administration, FDA, www.fda.gov.
[4]   | “Coronavirus Disease 2019 (COVID-19).” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, www.cdc.gov/coronavirus/2019-ncov/index.html.
[5]   | Isaac See, MD. “Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination.” JAMA, JAMA Network, 30 Apr. 2021, jamanetwork.com/journals/jama/fullarticle/2779731.
[6]   | Scully, Marie, et al. “Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 NCoV-19 Vaccination: NEJM.” New England Journal of Medicine, 16 Apr. 2021.
[7]   | Carli, Giuseppe, et al. “Deep Vein Thrombosis (DVT) Occurring Shortly after the Second Dose of MRNA SARS-CoV-2 Vaccine.” Internal and Emergency Medicine, vol. 16, no. 3, 2021, pp. 803-804.

[8]  
PINHO, Ana Catarina. “AstraZeneca's COVID-19 Vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Platelets.” European Medicines Agency, 8 Apr. 2021, www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.

[9]   | PINHO, Ana Catarina. “COVID-19 Vaccine Janssen: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Platelets.” European Medicines Agency, 22 Apr. 2021, www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.
[10]   | Torjesen, Ingrid. “Covid-19: Risk of Cerebral Blood Clots from Disease Is 10 Times That from Vaccination, Study Finds.” BMJ, 2021.
[11]   | Schultz, Nina H., et al. “Thrombosis and Thrombocytopenia after ChAdOx1 NCoV-19 Vaccination.” New England Journal of Medicine, 2021.
[12]   | Fadar Oliver Otite, et al. “Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States.” Neurology. 2020 Oct 20; 95(16): e2200-e2213. Epub 2020 Aug 26.
[13]   | Sharon Devasagayam, et al. “Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study.”PMID: 27435401.